Japan Lifeline saw the highest growth of 1.16% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.16% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Japan Lifeline’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Japan Lifeline has been focused on protecting inventions in Germany(DE) with four publications in Q2 2024
The Germany(DE) Patent Office dominates the patent filings with nearly 50% of filings. The Germany(DE), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Japan Lifeline is filings its patents. Among the top granted patent authorities, Japan Lifeline has 100% of its grants in European Patent Office(EPO).
Boston Scientific and Johnson & Johnson could be the strongest competitors for Japan Lifeline
Cardiovascular devices related patents lead Japan Lifeline portfolio followed by general surgery devices
Japan Lifeline has highest number of patents in cardiovascular devices followed by general surgery devices.
For comprehensive analysis of Japan Lifeline's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
